Cite
HARVARD Citation
Burmester, G. et al. (n.d.). SAT0137 PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE). Annals of the rheumatic diseases. pp. 1138-1139. [Online].